

## Disposition of Participants

|                            | Placebo |      | Xanomeline Low Dose |      | Xanomeline High Dose |      |
|----------------------------|---------|------|---------------------|------|----------------------|------|
|                            | n       | (%)  | n                   | (%)  | n                    | (%)  |
| Participants in population | 86      |      | 84                  |      | 84                   |      |
| Completed                  | 58      | 67.4 | 25                  | 29.8 | 27                   | 32.1 |
| Discontinued               | 28      | 32.6 | 59                  | 70.2 | 57                   | 67.9 |
| Adverse Event              | 8       | 9.3  | 44                  | 52.4 | 40                   | 47.6 |
| Death                      | 2       | 2.3  | 1                   | 1.2  | 0                    | 0.0  |
| I/E Not Met                | 1       | 1.2  | 0                   | 0.0  | 2                    | 2.4  |
| Lack of Efficacy           | 3       | 3.5  | 0                   | 0.0  | 1                    | 1.2  |
| Lost to Follow-up          | 1       | 1.2  | 1                   | 1.2  | 0                    | 0.0  |
| Physician Decision         | 1       | 1.2  | 0                   | 0.0  | 2                    | 2.4  |
| Protocol Violation         | 1       | 1.2  | 1                   | 1.2  | 1                    | 1.2  |
| Sponsor Decision           | 2       | 2.3  | 2                   | 2.4  | 3                    | 3.6  |
| Withdrew Consent           | 9       | 10.5 | 10                  | 11.9 | 8                    | 9.5  |

Source: ADSL dataset